Versant Capital Management, Inc Abb Vie Inc. Transaction History

Versant Capital Management, Inc

$454 Million
Q4 2024

A detailed history of Versant Capital Management, Inc transactions in Abb Vie Inc. stock. As of the latest transaction made, Versant Capital Management, Inc holds 2,735 shares of ABBV stock, worth $560,729. This represents 0.11% of its overall portfolio holdings.

Number of Shares

2,735

Previous 2,042 33.94%

Holding current value

$560,729

Previous $403,000 20.6%

% of portfolio

0.11%

Previous 0.09%

35 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jan 02, 2025	BUY	$164.99 - $203.87 $114,338 - $141,281	693 Added 33.94%	2,735 $486,000
Q3 2024 Oct 07, 2024	BUY	$163.84 - $199.33 $100,925 - $122,787	616 Added 43.2%	2,042 $403,000
Q2 2024 Jul 05, 2024	SELL	$154.79 - $180.76 $16,098 - $18,799	-104 Reduced 6.8%	1,426 $244,000
Q1 2024 Apr 03, 2024	SELL	$159.82 - $182.1 $111,234 - $126,741	-696 Reduced 31.27%	1,530 $278,000
Q4 2023 Jan 08, 2024	SELL	$137.6 - $154.97 $2,339 - $2,634	-17 Reduced 0.76%	2,226 $344,000
Q3 2023 Oct 11, 2023	BUY	$133.59 - $154.65 $4,408 - $5,103	33 Added 1.49%	2,243 $334,000
Q2 2023 Jul 10, 2023	SELL	$132.51 - $164.9 $1,192 - $1,484	-9 Reduced 0.41%	2,210 $297,000
Q1 2023 Apr 10, 2023	BUY	$144.61 - $166.54 $8,242 - $9,492	57 Added 2.64%	2,219 $353,000
Q4 2022 Jan 25, 2023	BUY	$138.31 - $165.87 $1,383 - $1,658	10 Added 0.46%	2,162 $0
Q3 2022 Dec 30, 2022	BUY	$134.21 - $153.93 $6,307 - $7,234	47 Added 2.23%	2,152 $289,000
Q2 2022 Aug 02, 2022	BUY	$137.62 - $174.96 $550 - $699	4 Added 0.19%	2,105 $322,000
Q1 2022 Apr 29, 2022	BUY	$131.98 - $163.75 $791 - $982	6 Added 0.29%	2,101 $341,000
Q4 2021 Jan 06, 2022	BUY	$107.43 - $135.93 $12,676 - $16,039	118 Added 5.97%	2,095 $284,000
Q3 2021 Oct 29, 2021	BUY	$106.4 - $120.78 $24,472 - $27,779	230 Added 13.17%	1,977 $213,000
Q2 2021 Jul 22, 2021	BUY	$105.21 - $117.21 $2,840 - $3,164	27 Added 1.57%	1,747 $197,000
Q1 2021 Apr 27, 2021	BUY	$102.3 - $112.62 $52,889 - $58,224	517 Added 42.98%	1,720 $186,000
Q4 2020 Feb 08, 2021	SELL	$80.49 - $108.67 $153,977 - $207,885	-1,913 Reduced 61.39%	1,203 $128,000
Q3 2020 Nov 02, 2020	BUY	$85.91 - $100.83 $945 - $1,109	11 Added 0.35%	3,116 $272,000
Q2 2020 Jul 16, 2020	BUY	$73.37 - $98.18 $3,008 - $4,025	41 Added 1.34%	3,105 $304,000
Q1 2020 Apr 17, 2020	BUY	$64.5 - $97.79 $9,288 - $14,081	144 Added 4.93%	3,064 $233,000
Q4 2019 Jan 28, 2020	SELL	$72.13 - $90.25 $2,596 - $3,249	-36 Reduced 1.22%	2,920 $258,000
Q3 2019 Oct 18, 2019	SELL	$62.98 - $75.72 $11,588 - $13,932	-184 Reduced 5.86%	2,956 $223,000
Q2 2019 Jul 16, 2019	SELL	$65.7 - $83.98 $20,958 - $26,789	-319 Reduced 9.22%	3,140 $228,000
Q1 2019 Apr 23, 2019	BUY	$77.14 - $90.79 $245,382 - $288,802	3,181 Added 1144.24%	3,459 $278,000
Q1 2019 Apr 23, 2019	SELL	$77.14 - $90.79 $274,155 - $322,667	-3,554 Reduced 92.75%	278 $278,000
Q3 2018 Oct 15, 2018	SELL	$88.91 - $98.84 $7,290 - $8,104	-82 Reduced 2.1%	3,832 $362,000
Q2 2018 Jul 06, 2018	SELL	$89.78 - $106.23 $1,616 - $1,912	-18 Reduced 0.46%	3,914 $362,000
Q1 2018 Apr 19, 2018	SELL	$92.01 - $123.21 $13,433 - $17,988	-146 Reduced 3.58%	3,932 $372,000
Q4 2017 Apr 19, 2018	BUY	$89.56 - $98.21 $27,226 - $29,855	304 Added 8.06%	4,078 $394,000
Q2 2017 Apr 23, 2018	BUY	N/A	10 Added 0.27%	3,774 $273,000
Q4 2016 Apr 23, 2018	SELL	N/A	-14 Reduced 0.37%	3,764 $235,000
Q3 2016 Apr 23, 2018	SELL	N/A	-28 Reduced 0.74%	3,778 $238,000
Q2 2016 Apr 23, 2018	SELL	N/A	-37 Reduced 0.96%	3,806 $235,000
Q1 2016 Apr 23, 2018	SELL	N/A	-26 Reduced 0.67%	3,843 $219,000
Q4 2015 Apr 23, 2018	BUY	N/A	3,869	3,869 $229,000

Others Institutions Holding ABBV

# of Institutions

4,097

Shares Held

1.28B

Call Options Held

16.7M

Put Options Held

15M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $362B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Versant Capital Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Versant Capital Management, Inc with notifications on news.

Account

Versant Capital Management, Inc Abb Vie Inc. Transaction History